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Newborns are colonized with an intestinal microbiota
shortly after birth, but the factors governing the reten-
tion and abundance of specificmicrobial lineages are
unknown. Nursing infants consume human milk
oligosaccharides (HMOs) that pass undigested to
the distal gut, where they may be digested by
microbes.Wedetermined that theprominent neonate
gut residents, Bacteroides thetaiotaomicron and
Bacteroides fragilis, induce the same genes during
HMO consumption that are used to harvest host
mucus glycans, which are structurally similar to
HMOs. Lacto-N-neotetraose, a specificHMOcompo-
nent, selects for HMO-adapted species such as
Bifidobacterium infantis, which cannot use mucus,
and provides a selective advantage to B. infantis
in vivo when biassociated with B. thetaiotaomicron
in the gnotobiotic mouse gut. This indicates that
the complex oligosaccharide mixture within HMOs
attracts both mutualistic mucus-adapted species
and HMO-adapted bifidobacteria to the infant intes-
tine that likely facilitate both milk and future solid
food digestion.
INTRODUCTION
The infant gut undergoes a complex and unpredictable process
of colonization during the first months of life, characterized by
extreme fluctuations in overall density andmembership (Koening
et al., 2011; Palmer et al., 2007). Factors that drive microbiota
assembly remain poorly understood. Several studies indicate
that breast-milk versus formula feeding can play a large role in
infant intestinal microbiota composition (Adlerberth and Wold,
2009). Humanmilk oligosaccharides (HMOs), a class of carbohy-
drates within human milk, may promote intestinal colonization of
specific subsets of microbes (Engfer et al., 2000). HMOs are
composed of more than 200 structurally distinct oligosaccha-Cell Host &rides that occur at high concentrations (20 g/L in colostrums;
5–12 g/L in mature milk). The wide diversity of structures
includes linear or branched lactosamine chains (Galb1-3/4,
GlcNAcb1-3/6) extended from a lactose (Galb1-4Glc) core.
Structural variability is due to the addition of the terminating
sugars N-acetylneuraminic acid (Neu5Ac) in a2-3 or a2-6 link-
ages and/or fucose in a1-2, a1-3, or a1-4 linkages (reviewed in
Chichlowski et al., 2011). The complete degradation of HMOs
requires an extensive set of glycoside hydrolases and/or
membrane transporters that humans lack in the small intestine.
In the lower part of the intestine, HMOs theoretically can be
used by members of the infant intestinal microbiota and
thereby promote HMO-utilizing microbes. The ability of certain
Bifidobacterium species to consume HMOs has been demon-
strated and genome sequencing of HMO-utilizing Bifidobacte-
rium isolates has revealed genes involved in HMO uptake,
degradation, and metabolism (Sela et al., 2008; LoCascio
et al., 2007). Recently, it has been described that HMO utilization
is not exclusive to certain Bifidobacterium, since members from
the genus Bacteroides can use milk glycans as a sole carbon
source (Marcobal et al., 2010).
Bacteroides species are variably abundant in the infant
gastrointestinal microbiota, but by the first year of life they are
consistently present in the gut (Palmer et al., 2007). These
species are well adapted to use a multitude of both dietary poly-
saccharides and host-derived glycans (e.g., mucus), due to
specialized machinery encoded by polysaccharide utilization
loci (PULs) (Martens et al., 2008). PULs have been widely
expanded within the genomes ofBacteroides, and each appears
to be specialized in the use of a particular class of carbohydrates
(Martens et al., 2008; Sonnenburg et al., 2010). The ability of
Bacteroides to utilize HMOs suggests that specific PULs within
these Bacteroides genomes are involved in HMO use.
Using Bacteroides thetaiotaomicron (Bt) and Bacteriodes
fragilis (Bf), two of the predominant Bacteroides species found
in the gut of neonates (Rotimi and Duerden, 1981), we have
demonstrated that each species induces a common set of genes
when growing in host mucin glycans or HMOs. However, these
genes are not conserved between Bt and Bf. These data sug-
gest that HMO use is either a convergent functionality between
members of the genus or relies upon pathways that have beenMicrobe 10, 507–514, November 17, 2011 ª2011 Elsevier Inc. 507
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Figure 1. B. thetaiotaomicron Upregulates Numerous Glycoside Hydrolases during Consumption of HMO
(A) Schematic of HMO linkages (branched, top box; linear, bottom box) and putative HMO active glycoside hydrolase families (GH) (Wu et al., 2010). Linkages are
to the 1-carbon of the underlying sugar unless otherwise noted.
(B) In vitro growth of Bacteroides species in MM-HMO.
(C) Bt gene expression at two time points (HMO1, HMO2) in MM-HMO relative to MM-glucose for 24 putative HMO active GHs (predicted to hydrolyze linkages
found in milk glycans in A). See Table S1 for full list of genes upregulated in all tested carbon sources.
(D)BtHMO consumption at two time points (HMO1, HMO2), determined byMALDI-FTICR-MS. Peak IDs correspond to a characteristic oligosaccharide, with the
following discrete mass to charge ratios (m/z): A, 732.25; B, 878.31; C, 1024.36; D, 1097.38; E, 1243.44; F, 1389.50; G, 1462.51; H, 1535.55; I, 1608.57;
J, 1754.63; K, 1827.64; L, 1900.69; M, 1973.70; N, 2119.76; O, 2265.82; P, 2484.89. Number of monosaccharides for each mass is indicated. See Figure S1 for
detailed structural information for each oligosaccharide. Error bars represent standard deviation for three biological replicates.
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utilization. The ability of the short HMO, lacto-N-neotetraose
(LNnT), to selectively expand the HMO-using Bifidobacterium
infantis (Bi) relative to Bt in gnotobiotic biassociated mice
suggests that milk oligosaccharides play a dual role in selecting
for species that are HMO or mucus adapted.
RESULTS
B. thetaiotaomicron Exhibits an Expansive Glycoside
Hydrolase Response during Consumption of HMOs
In Vitro
Bt possesses a repertoire of predicted glycoside hydrolases
(GH) capable of accommodating the structural diversity found
in milk oligosaccharides. Among Bt’s > 260 glycoside hydro-
lases, 67 make up six GH families with predicted activities
required to process linkages found in HMOs (Figure 1A). Bt
grows efficiently when cultured in minimal medium containing
HMO (1.5% w/v; MM-HMO) as the sole carbon source. Five508 Cell Host & Microbe 10, 507–514, November 17, 2011 ª2011 Elsadditional sequenced Bacteroides species, Bf, B. caccae,
B. vulgatus, B. ovatus, and B. stericoris, all grow in the presence
of HMOs. Growth of Bf, B. vulgatus, and B. caccae are compa-
rable to that of Bt (doubling times of 2.9 hr, 3.3 hr, and 2.8 hr,
respectively; saturating OD600 > 0.9 for each strain). B. ovatus
and B. stercoris do not exhibit exponential growth in MM-
HMO, indicating that efficient use of milk oligosaccharides is
not universal in the gut resident Bacteroides (Figure 1B).
We identified the Bt genes induced by HMOs using transcrip-
tional profiling of Bt during growth in MM-HMO at the midpoints
of the two logarithmic growth phases, using aBtGeneChip (n = 2
biological replicates/growth phase, four datasets total) (Fig-
ure 1C). As a baseline for comparison, we used previously re-
ported data of Bt grown in MM-glucose (Martens et al., 2008).
A total of 156 genes are significantly upregulated during the first
phase, and 230 genes are upregulated during the second phase,
relative to MM-glucose (see Experimental Procedures for criteria
used to define significance; see Table S1 for complete list).
Forty-six genes of the 253-gene response to HMOs areevier Inc.
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HMO Consumption by Bacteroidespredicted to encode glycoside hydrolases, and over half of those
(24 genes) belong to the seven GH families that target the most
common linkages found within HMOs (Figures 1A and 1C).
The biphasic growth of Bt in MM-HMO suggests a sequential,
ordered degradation of glycans. We used laser desorption/ioni-
zation coupled with mass spectrometry to characterize the
consumption of 16 structurally defined neutral milk oligosaccha-
rides, which represents >85% of the total HMO pool (LoCascio
et al., 2007). After the completion of each exponential phase,
HMOs were purified from culture supernatants, reduced, and
profiled (Marcobal et al., 2010). During the first growth phase,
Bt consumes the full spectrum of HMOs; a slight preference
for larger oligosaccharides is apparent (Figure 1D). After the
second phase all the glycans are depleted >80%, with the
exception of the smallest oligosaccharide mass (Figure 1D,
Peak A), which corresponds to two isomers present at
high concentration in the HMO pool: lacto-N-tetraose (LNT,
Galb1-4GlcNAcb1-3Galb1-4Glc) and LNnT (Galb1-3GlcNAcb1-
3Galb1-4Glc) (see Figure S1). Bt exhibits no preference for fuco-
sylated or nonfucosylated glycans. These data demonstrate Bt’s
capacity to utilize of a broad range of HMOs, adding to its previ-
ously described saccharolytic capacity for mucus glycans and
plant polysaccharides (Sonnenburg et al., 2005).
B. thetaiotaomicron HMO Use Is Coupled to
Upregulation of Mucin Glycan Degradation Pathways
To identify which portion of the Bt transcriptional response in
MM-HMO was due to the complex oligosaccharides versus
the simple core sugars, lactose and galactose, we performed
transcriptional profiling of Bt grown in MM-galactose and
MM-lactose (n = 2 mid-log phase for each monophasic growth)
(Figure S2A). Comparison of these data with the baseline
MM-glucose revealed 40 and 34 Bt genes are significantly upre-
gulated (>5-fold) in MM-galactose and MM-lactose, respec-
tively. Thirty-two of the 137 genes that were upregulated at least
5-fold in the MM-HMO response were also upregulated in the
presence of galactose and/or lactose, consistent with the pres-
ence of these simple sugars in the core structures of all HMOs
(Figure S2B). The 105 genes that were upregulated in either
phase of HMO growth and not in MM-galactose or MM-lactose
were highly enriched in the COG functional group ‘‘carbohydrate
metabolism and transport’’ (32.1% compared with 11% repre-
sentation across the genome) (Figure S2C). These data suggest
that this 105-gene signature captures the Bt response to the
structural complexity within HMOs.
Eighty of the 105 HMO-specific genes are found within ten
PULs (loci involved in oligosaccharide acquisition and degrada-
tion). The larger 253-gene group that is upregulated in both
phases of HMO growth included regions of three additional
PULs, which resulted in 13 PULs or partial PULs upregulated in
one or both phases of HMO growth (Figure 2A). Three of these
PULs encode putative fucosidases, key enzymes that hydrolyze
the terminal fucose residues from HMOs (BT1624–BT1632,
BT3172–BT3173, BT4132–BT4136) and three endo-b-N-acetyl-
glucosaminidases. Average fold changes for genes within each
PUL or partial PUL ranged from 8- to 173-fold (Table S2).
Bt profiles in previously defined conditions were examined
to search for overlap with the HMO response. Substrate spe-
cificities of several Bt PULs have been inferred using growthCell Host &conditions in which Bt is reliant upon host-derived gut mucus
glycans. We compared our in vitro Bt HMO growth expression
data with that from three different experimental paradigms in
which Bt is reliant upon host mucus glycans: (i) in vitro growth
in purified porcine mucus glycans (PMG) (n = 3 replicates/growth
phase, 2 time points, during exponential phases from biphasic
growth) (Martens et al., 2008); (ii) in vivo Bt-colonized 17-day-
old gnotobiotic suckling mice (n = 6 samples) (Bjursell et al.,
2006); and (iii) in vivo Bt-colonized adult gnotobiotic mice that
were fed a diet lacking complex glycans (n = 3 samples) (Son-
nenburg et al., 2005). Transcriptional profiles were analyzed
using Bt grown in MM-glucose in vitro as a baseline (Table S2
lists genes upregulated in at least one condition).
Nine of the 13 upregulated PULs or partial PULs in MM-HMO
were also highly upregulated (R10-fold induction) in one or more
of the conditions of Bt grown in mucin glycans (Figure 2A). This
overlap between HMO- and mucin-induced genes presents
the possibility that Bt responds to common structural motifs
found in oligosaccharides from mother’s milk and intestinal
mucin glycans. For instance, in all datasets we observed in-
creased expression of the PUL BT2818–BT2826, which encodes
glycoside hydrolases predicted to cleave linkages from
Galb-GlcNAcb-Gal, a structure common to HMOs and mucins.
Alternatively, four Bt PULs exhibited increased expression
specific to HMOs: three complete PULs (BT2618–BT2633,
BT3172–BT3173, and BT3958–BT3965) and one partial PUL
(BT3172–BT3173) (Figure 2A). These data indicate that Bt
responds to aspects of the milk-derived glycans that are not
found appreciably in the mucin preparations.
Comparing the structures of HMOs and human intestinal
mucin glycans, it is apparent that HMOs exhibit less structural
complexity (Karlsson et al., 1997; Robbe et al., 2004; Robbe
et al., 2003a; Robbe et al., 2003b; Thomsson et al., 2002) (Fig-
ure 2B). Mucin glycans are typically built upon an N-acetyl-
galactosamine that is O-linked to serine and threonine residues
of the mucin protein, and the most abundant are based on five
different core structures. Milk oligosaccharides are elaborated
from a galactose of the ‘‘core’’ lactose disaccharide that is
analogous to the reducing GalNAc of mucin O-linked glycans;
structures similar to core 3 [GlcNAcb1-3Gal] and core 4
[GlcNAcb1-3(GlcNAcb1-6)Gal] are present in HMOs. Structures
very similar to human mucin glycans are found in the porcine
and mouse mucin glycans, which have been used experimen-
tally to define Bt’s mucus use capability (Martens et al., 2008)
(Figure 2B). In both the intestinal mucins and in HMOs, repeated
motifs containing galactose and N-acetylglucosamine are
present and terminate with fucose and sialic acid residues. The
extensive structural similarity between HMOs and mucins
provides a parsimonious explanation for Bacteroides species
upregulating the same PULs for the utilization of glycans from
these two different sources.
We tested if the HMO-induced PULs are required for HMO
consumption by creating Btmutants in four of the HMO-specific
loci. In-frame deletions for the respective susC-like genes, in-
volved in carbohydrate binding, and the fucosidase BT4136 con-
taining PUL (the most upregulated HMO-responsive glycoside
hydrolases in Bt) were constructed, but showed no defect in
growth in HMOs in vitro (see Figure S2D). These data indicate
that extensive degeneracy exists within Bt’s HMO response,Microbe 10, 507–514, November 17, 2011 ª2011 Elsevier Inc. 509
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Figure 2. B. thetaiotaomicron Upregulates Mucus-Utilization Loci during HMO Consumption
(A) Gene expression profile of Bt’s induced PULs or partial PULs (*) in MM-HMO, MM-porcine mucin glycans (PMG), or host intestinal glycans from adult or
suckling mice relative to MM-glucose. Parentheses denote sample number per condition. See also Figure S2 and Table S2.
(B) Schematic ofmucin glycans based on previous reports (Hurd et al., 2005; Karlsson et al., 1997; Robbe et al., 2004; Robbe et al., 2003b; Thomsson et al., 2002).
Structural information includes the core, extended core, and terminal (fucosylation, sialylation) motifs.
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fructan-utilization locus (Sonnenburg et al., 2010).
B. fragilis Upregulates a Distinct Set of Mucin-Use
Genes when Consuming HMOs
The HMO-induced Bt susC/susD homologs and genes located
adjacent to the susC/susD genes were used as markers of
HMO-utilization genes to identify the presence or absence of
orthologs across five sequenced Bacteroides (Bf, B. caccae,
B. ovatus, B. ovatus, and B. stercoris). In cases where a species
shares an orthologous susC/susD pair with Bt, adjacent genes
within the PUL generally display a lack of conservation (Fig-
ure S3). Bf grows efficiently in MM-HMOs (Figure 1B), but does
not show conservation of any of the HMO-utilization PULs iden-
tified in Bt. These results suggest that Bacteroides species have
developed diverse strategies for using HMOs with varying levels
of efficiency.
Whole genome transcriptional profiling of Bf at mid-log phase
of its monophasic growth in either MM-HMO, MM-lactose,
MM-galactose, or MM-glucose was used to identify the genes
upregulated by Bf during HMO consumption. MM-glucose
served as a baseline to define the genes that were upregulated
in HMO, but were not upregulated in MM-lactose or MM-galac-510 Cell Host & Microbe 10, 507–514, November 17, 2011 ª2011 Elstose (n = 2 per condition). These data revealed a Bf response to
HMO composed of a much smaller set of genes compared to Bt.
We identified 21 genes specifically upregulated (>5-fold) by Bf in
HMO (See Table S3) compared to 105 genes by Bt. Just four Bf
susC/susD-homolog-containing PULs were upregulated in HMO
compared to 13 in Bt (Figure 3A).
Twelve of the 21 HMO-specific Bf genes were distributed
within two loci that are dedicated to sialic acid acquisition and
catabolism (Brigham et al., 2009) (Figure 3B). These genes
include a neuraminidase (nanH, BF1806), an N-acetyl neurami-
nate permease (nanT, BF1724), an N-acetylneuraminate lyase
(nanL, BF1712), and an N-acetylmannosamine 2-epimerase
(nanE, BF1713) (upregulated 7.8-fold, 5.8-fold, 6.9-fold, and
6.0-fold, respectively) and provide the machinery necessary
to cleave and catabolize Neu5Ac from sialylated glycans. To
confirm that Bf does in fact consume sialic acids from HMOs,
sialic acid content in the MM-HMO after growth was measured
before and after acid hydrolysis using derivatization with 1,2-di-
amino-4,5-methylenedioxybenzene followed by reverse phase
HPLC. The sialic acid Neu5Ac was completely depleted by Bf
after growth in HMO. In contrast, Bt can cleave Neu5Ac from
sialylated HMOs, presumably to access underlying sugars, but
is unable to catabolize it (Figure 3C).evier Inc.
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Figure 3. B. fragilis Response to HMOs Includes Sialic Acid Catabolism
(A) Bf susC/susD homologs upregulated (fold change) in vitro in MM-galactose, MM-lactose, and MM-HMO relative to MM-glucose. See also Figure S3.
(B) Genomic organization of Bf genes with >5-fold induction in MM_HMO relative to MM-glucose. Yellow boxes frame genes related to sialic acid consumption.
White genes are upregulated <5 fold. Table S3 lists all significant HMO upregulated genes.
(C) HMO-bound versus liberated Neu5Ac content in MM-HMO and in MM-HMO after Bf and Bt growth. Error bars represent standard error for three biological
replicates.
(D) Fold-induction of sialic acid-related genes from Bf grown in MM-O-PMG and MM-HMO relative to growth in MM-glucose, as measured by qRT-PCR.
Error bars represent standard error for three biological replicates.
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gies used for accessing HMOs and mucin glycans similar to
that observed in Bt. The expression of genes that represent
the Bf response to HMOs (BF1712, BF1713, BF1714, and
BF1806) in MM supplemented with the O-glycan fraction from
porcine mucin (MM-O-PMG) and MM-glucose was measured
by qRT-PCR. We found that all four genes are upregulated in
the presence of mucin, confirming that Bf upregulates sialic
acid-use pathways in the consumption of both HMOs and intes-
tinal mucin (Figure 3D). Therefore, while the specific PULs em-
ployed for HMO use by Bf and Bt differ, the mobilization of
mucin-use PULs for HMO consumption is conserved between
these Bacteroides species.
B. thetaiotaomicron and Bifidobacterium infantis
Differentially Consume the Structurally Similar Mucin
Glycans and HMO
Previous work has demonstrated that Bifidobacterium species
are well adapted to HMO use (Sela and Mills, 2010). We grew
an HMO-consuming Bifidobacterium strain that is abundant in
the microbiota of breast-fed infants, Bi, in purified porcine mucin
glycans (MM-O-PMG) to elucidate its competence in mucin
consumption (Haarman and Knol, 2006). Despite its proficiency
at HMO use, Bi fails to grow in the MM-O-PMG (Figure 4A).
These data suggest that structures unique to HMOs (i.e., not
found in mucin glycans) are responsible for supporting growth
of the HMO-adapted Bifidobacterium strain. Bi has previouslyCell Host &been shown to exhibit a preference for the smaller oligosaccha-
rides found in HMOs, some of which are structurally distinct from
mucin glycans (LoCascio et al., 2007). One such simple oligosac-
charide is the four-sugar LNnT (Galb1-3GlcNAcb1-3Galb1-
4Glc). Therefore, we grew both Bt and Bi in a pure preparation
of this single human milk oligosaccharide (MM-LNnT). Bi grew
efficiently reaching a high OD, while Bt did not (Figure 4A).
These results suggest a model in which the structural com-
plexity of HMOs includes structures that represent mucin
glycans that may promote colonization ofmucin-adapted symbi-
onts, like Bacteroides, early in life. HMOs also contain structures
distinct from mucins, such as LNnT, which may provide a niche
for species that are important in microbiota assembly but that
are not well adapted to mucus, like Bi, and would otherwise be
outcompeted by mucus-adapted species like Bacteroides. The
incomplete overlap of these glycan structural features allows
HMOs to attract both HMO-adapted Bifidobacterium species
and mucus-adapted Bacteroides species simultaneously
(Figure 4B).
We performed an in vivo experiment to test whether LNnT
could exhibit selectivity in vivo, enabling the expansion of a
Bifidobacterium species in the presence of a Bacteroides
species. Two groups of 6-week-old germ-free mice were fed a
polysaccharide-deficient diet, forcing a reliance on host mucus
glycans for carbon and energy. One group received LNnT
supplementation in the water (1% w/v; average consumption
of 75 mg of LNnT daily), the control group received plain water.Microbe 10, 507–514, November 17, 2011 ª2011 Elsevier Inc. 511
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Figure 4. Selective Use of the HMO Lacto-
N-Neotetraose by B. infantis Provides
In Vivo Advantage
(A) In vitro growth of Bt and B. infantis in the
presence of MM-O-PMG, MM-HMO, or MM-
LNnT.
(B) Venn diagram representing the structural rela-
tionship of mucin and milk glycans. HMOs include
a subset of structures found in mucus that can be
consumed by mucus-adapted mutualists (e.g.,
Bacteroides). B. infantis is adapted to use simple
structures within HMOs (e.g., LNnT) and is unable
to use the structures found in mucin glycans.
(C) Bt and B. infantis biassociation of adult germ-
free mice fed a polysaccharide-deficient diet
without (black circles) or with LNnT (red squares).
Values represent average of fecal communities
within each group (n = 4 mice/group).
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equivalent quantities of Bt and Bi (108 CFU each). At day 6 post-
inoculation, the group receiving LNnT was switched to normal
water; at day 15 postinoculation, LNnT was readministered
for 3 additional days. Total bacterial colonization density was
determined by assessing the CFUs in feces over the course of
the 18 day experiment.
The administration of LNnT resulted in an expanded popula-
tion of Bi relative to Bt throughout the first period (day 1–6)
compared to control (41.5 ± 6.4% versus 2 ± 0.5% on day 6;
p = 0.009, day 6, n = 4 mice) (Figure 4C). LNnT supplementation
was withdrawn on day 6 and colonization density was deter-
mined on days 7, 8, 9, 12, and 15 post colonization (1, 2, 3, 6,
and 9 days after removing LNnT from the water). Removal of
LNnT resulted in a drop in Bi to levels similar to controls within
2 days. At day 3 post withdrawal of LNnT, Bi representation
was 3.9 ± 0.2%compared to 41.5 ± 6.4% just prior to withdrawal
(p = 0.006, day 6 versus day 9, n = 4 mice). LNnT was reintro-
duced into the water on day 15, and bacterial colonization was
monitored at days 16, 17, and 18 post colonization. Two days
after LNnT reintroduction, Bi expanded from 0.5 ± 0.5% at day
15 to 49.9 ± 2% at day 17 (p = 0.012, day 15 versus day 17,
n = 4 mice). By day 18, Bi represented 25.9 ± 9.6% of the
community in LNnT-fed mice, compared to 1.9 ± 1.5% in the
control group (p = 0.014, n = 4 mice) (Figure 4C). These results
confirm that this short milk oligosaccharide provides a selective
advantage to a Bifidobacterium species over a Bacteroides
species in vivo.
DISCUSSION
HMOuse byBt andBf results in the induction of PULs involved in
mucin consumption. One important question is whether HMOs
or mucin was the primary selective force shaping locus function-
ality. For strains that are strictly adapted to one of the glycan512 Cell Host & Microbe 10, 507–514, November 17, 2011 ª2011 Elsevier Inc.sources, the selective pressure can be
more confidently assigned, such as Bi’s
adaptation to HMOs. However for Bt, it
is less clear whether (i) adaptation to
mucin glycans provides extant pathwaysthat may bemobilized for HMO use or (ii) HMOs play a significant
role inBt propagation and provide a selective force, in addition to
mucin, that shapes multifunctional loci adapted to accommo-
date the unique structural aspects of HMOs and mucin glycans.
The inability of Bt to readily consume LNnT argues against the
latter. If Bt’s entire HMO response is a result of HMO glycans
co-opting extant pathways, it is unclear why a subset of Bt’s
transcriptional response to HMOs includes loci that are not
induced by mucin use. Considering the more diverse carbohy-
drate structures that human mucus contains, compared to the
pig or mouse mucin glycans, it is possible that the set of Bt
genes identified as mucin-glycan responsive is not exhaustive.
Specifically, the complete set of Bt genes responsive to human
mucus, once defined, may include the loci that now appear to
be ‘‘HMO-specific.’’
The lack of requirement of the HMO-specific loci for efficient
growth in HMOs by Bt, as demonstrated by our gene deletion
studies, may appear to support that these loci are not HMO-
adapted, but rather are co-opted by the structurally similar
HMOs. However, mutation of five mucin-glycan-use PULs in a
quintuple KOstrain ofBt did not reveal a profound growth pheno-
type during use of mucin glycans in vitro (Martens et al., 2008).
Rather, the requirement of these PULs became apparent upon
competition with the WT parent strain in vivo. Therefore, our
results highlight the caveats associated with assessing the
importance of a gene or locus of a gut resident in a noncompeti-
tive environment. Due to the paucity of pure and complex HMOs,
in vivo competition experiments are not currently possible.
One hypothesis that arises from this work is that HMO struc-
tures mimic mucus glycans to attract mucin-adapted resident
mutualists to an infant microbiota. Attraction of Bacteroides
may provide the additional benefit of seeding the community
with species that are also well adapted to dietary glycan use,
thus preparing the infant microbiota for a smooth transition
upon the introduction of solid food. This possibility is supported
Cell Host & Microbe
HMO Consumption by Bacteroidesby recent metagenomic studies that have revealed an abun-
dance of plant polysaccharide-degrading glycoside hydrolases
within the gut microbiomes of breast-fed infants (Koening
et al., 2011; Vaishampayan et al., 2010). At the same time, unique
structural features of HMOs, such as LNnT, are potentially
important in shaping the infant microbiota in ways that are inde-
pendent of mucus use.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Culture Conditions
Bacterial strains used are listed in Supplemental Experimental Procedures.
Type strains were used unless otherwise indicated. Bacteroides species
were grown in tryptone-yeast extract-glucose (TYG) medium and minimal
medium (MM) (Martens et al., 2008). Bi was grown in Reinforced Clostridial
Medium (RCM) (Becton Dickinson, MD) and minimal medium consisting of
modified deMan-Rogosa-Sharpe medium (MRS) (Oxoid, Basingstoke, Hamp-
shire, UK), which lacks glucose. Carbon sources were added at 0.5% (w/v) to
the respective MM for Bacteroides or Bifidobacterium with the exception of
HMO, LNnT, and PMG, which were added at 1.5% (w/v). OD600 wasmonitored
using a BioTek PowerWave 340 plate reader (BioTek, Winooski, VT) every
30 min, at 37C anaerobically (6% H2, 20% CO2, 74% N2).
Whole Genome Transcriptional Profiling
Transcriptional profiling of Bt and Bf was performed in MM supplemented
with milk oligosaccharides, glucose, galactose, and lactose (Sigma-Aldrich).
Bt samples profiled in HMO were collected at OD600 = 0.5 and OD600 = 0.8.
Cultures grown on galactose, lactose, and glucose were collected at
OD600 = 0.5. RNA targets were prepared and hybridized to custom Bt Affy-
metrix GeneChips or Bf GeneChips (Sonnenburg et al., 2005). (See Supple-
mental Experimental Procedures for Bf GeneChip generation and validation
and GeneChip data analysis).
Genetic Manipulation of B. thetaiotaomicron
Genetic manipulation of Bt was performed using counterselectable allele
exchange, resulting in ‘‘in-frame’’ gene deletion (Martens et al., 2008).
Glycoprofile Analysis of HMO Consumption
Bacteria culture supernatants in MM-HMO were collected by centrifugation.
Remaining oligosaccharides were recovered and profiled by HiRes matrix-
assisted laser desorption/ionization-Fourier transform ion cyclotron reso-
nance mass spectrometry (MALDI-FTICR-MS) (Marcobal et al., 2010).
Sialic Acid Content Determination
Culturesupernatantwas isolatedaftergrowth inMM-HMOandclarifiedbycentri-
fugation and filtration. Sialic acid concentrations were determined by the Glyco-
technology Core Facility UCSD (University of California, San Diego, San Diego,
CA), using the Sigma DMB labeling kit protocol (Prozyme, San Leandro, CA).
Competitive Colonization of Gnotobiotic Mouse
Germ-free Swiss-Webstermicewere reared in gnotobiotic isolators and fed an
autoclaved polysaccharide-deficient diet (BioServ, http://bio-serv.com) in
accordance with A-PLAC, the Stanford IACUC. Mice were biassociated using
oral gavage (108 CFU of each species). Subsequent community enumerations
from mice were determined from freshly collected feces, by selective plating
of serial dilutions in RCM agar and BHI-blood agar supplemented with
gentamicin (200 mg/ml). Significant differences between sample groups
were determined using Student’s t test. Synthetic LNnT (Glycom A/S, Den-
mark) was purified by crystallization to a final purity of >99%. Characterization
was performed using multiple methods, including NMR (1D and 2D) mass-
spectrometry, and HPLC.
ACCESSION NUMBERS
GeneChip data files have been deposited to the Gene Expression Omnibus
under accession numbers GSE26772 and GSE32207.Cell Host &SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, Supplemental Experimental
Procedures, Supplemental References, and three tables and can be found
with this article online at doi:10.1016/j.chom.2011.10.007.
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